lung cancer - search results

A mouse study by researchers at the Australian National University (ANU) and the Peter MacCallum Cancer Centre have discovered that a protein called Menin contributes to abnormal deactivation of specific genes in cancer cells.

Research published today in JAMA Surgery from the Washington University School of Medicine has found that the quality of lung cancer surgery in the United States varies widely with patients whose surgery failed to meet established guidelines experiencing significantly worse outcomes.

Boston scientists create “Sibyl”—an artificial intelligence tool able to accurately predict the risk of lung cancer in smokers and non-smokers.

In this Inside Precision Medicine Webinar, our distinguished guest, Dr. Sandip Patel from UCSD, discussed the importance of comprehensive genomic profiling in lung cancer and other solid tumors to direct optimal standard of care for cancer patients. Dr. Robin Thomas presented data from a study evaluating the AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit.

A combination of bacterial therapy with other treatment modalities may improve cancer treatment efficacy without additional toxicity, according to a report from Columbia Engineering researchers. They have developed a new approach for preclinical evaluation of bacterial therapies in lung cancer models.

The FDA approved the imaging agent Cytalux (pafolacianine) for use in lung cancer cases to help surgeons find and remove previously unidentified tumors.

Using low-dose CT to screen for lung cancer can dramatically improve survival for individuals diagnosed with early-stage cancer during the process, show results presented at the annual meeting of the Radiological Society of North America.

A new study in mice by Northwestern Medicine researchers demonstrates and describes a new gene that is responsible for activating an aggressive subtype of small-cell lung cancer. Findings that may lead to improved approaches and treatments.

Scripps researchers observed mice that were exposed to the irregular, shifting light patterns had an increased tumor burden of 68% and found the culprit to be the heat shock factor 1 (HSF1) family of proteins, not previously associated with circadian disruption.

Lung cancer patients with a KRAS G12C mutation showed benefits from Amgen’s KRAS inhibitor Lumakras compared with docetaxel.